atorvastatin actavis 40 mg apvalkotās tabletes
actavis group ptc ehf., iceland - atorvastatīns - apvalkotā tablete - 40 mg
siranalen 150 mg cietās kapsulas
medochemie ltd., cyprus - pregabalīns - kapsula, cietā - 150 mg
siranalen 75 mg cietās kapsulas
medochemie ltd., cyprus - pregabalīns - kapsula, cietā - 75 mg
atorvastatin actavis 80 mg apvalkotās tabletes
actavis group hf, iceland - atorvastatīns - apvalkotās tabletes - 80 mg
quetiapine accord 150 mg ilgstošās darbības tabletes
accord healthcare b.v., netherlands - kvetiapīns - ilgstošās darbības tablete - 150 mg
jyseleca
gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
onelar 30 mg zarnās šķīstošās cietās kapsulas
medochemie ltd., cyprus - duloksetīns - zarnās šķīstošā kapsula, cietā - 30 mg
onelar 60 mg zarnās šķīstošās cietās kapsulas
medochemie ltd., cyprus - duloksetīns - zarnās šķīstošā kapsula, cietā - 60 mg
cibinqo
pfizer europe ma eeig - abrocitinib - dermatīts, atopisks - citi dermatoloģiski preparāti - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
hemgenix
csl behring gmbh - etranacogene dezaparvovec - hemophilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.